Eterna Therapeutics Inc Total Assets
Eterna Therapeutics Inc total assets. Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) holds total assets worth $6.32 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ERNA company net worth for the company's overall valuation and market capitalisation.
Total Assets of Eterna Therapeutics Inc (2006–2025)
Total assets of Eterna Therapeutics Inc from 2006 to 2025. This chart illustrates how Eterna Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Eterna Therapeutics Inc (ERNA) stock price for real-time trading data and today's change.
Eterna Therapeutics Inc - Asset Composition Analysis
Eterna Therapeutics Inc Total Assets Breakdown (December 2025)
Eterna Therapeutics Inc total assets breakdown as of December 2025. Eterna Therapeutics Inc's total assets of $6.32 Million consist of 53.7% current assets and 46.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.3% |
| Accounts Receivable | $95.00K | 1.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $2.04 Million | 35.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Eterna Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Eterna Therapeutics Inc (ERNA) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eterna Therapeutics Inc's current assets represent 53.7% of total assets in 2025, a decrease from 60.5% in 2006.
- Cash Position: Cash and equivalents constituted 32.3% of total assets in 2025, up from 0.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 35.0% of total assets.
Eterna Therapeutics Inc Competitors by Total Assets
Key competitors of Eterna Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Eterna Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.01 | 1.81 | 5.65 |
| Quick Ratio | 2.01 | 1.81 | 5.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.96 Million | $2.14 Million | $21.20 Million |
Eterna Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Eterna Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.46 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | 10.7% |
| Total Assets | $5.83 Million |
| Market Capitalization | $2.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Eterna Therapeutics Inc's assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Eterna Therapeutics Inc's assets grew by 10.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eterna Therapeutics Inc (2006–2025)
The table below shows the annual total assets of Eterna Therapeutics Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.83 Million | +10.72% |
| 2024-12-31 | $5.27 Million | -89.28% |
| 2023-12-31 | $49.13 Million | +120.53% |
| 2022-12-31 | $22.28 Million | -29.33% |
| 2021-12-31 | $31.52 Million | +144.27% |
| 2020-12-31 | $12.91 Million | -15.51% |
| 2019-12-31 | $15.28 Million | +2.77% |
| 2018-12-31 | $14.86 Million | -10.30% |
| 2017-12-31 | $16.57 Million | -3.30% |
| 2016-12-31 | $17.14 Million | +1.86% |
| 2015-12-31 | $16.82 Million | -24.45% |
| 2014-12-31 | $22.27 Million | +44.06% |
| 2013-12-31 | $15.46 Million | +22.13% |
| 2012-12-31 | $12.66 Million | +8.66% |
| 2011-12-31 | $11.65 Million | -11.26% |
| 2010-12-31 | $13.12 Million | -8.20% |
| 2009-12-31 | $14.30 Million | +22.59% |
| 2008-12-31 | $11.66 Million | -44.09% |
| 2007-12-31 | $20.86 Million | -21.36% |
| 2006-12-31 | $26.52 Million | -- |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for… Read more